<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013232</url>
  </required_header>
  <id_info>
    <org_study_id>ARI201206</org_study_id>
    <nct_id>NCT02013232</nct_id>
  </id_info>
  <brief_title>Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia</brief_title>
  <official_title>Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing HuiLongGuan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing HuiLongGuan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperprolactinemia is a frequent consequence of treatment with typical antipsychotic agents
      and atypical antipsychotics such as risperidone. Recent studies have suggested that
      aripiprazole, a partial dopamine agonist, reduces the prolactin response to antipsychotics.
      Thus, we conducted this study to evaluate the dose effects of adjunctive treatment with
      aripiprazole on hyperprolactinemia in stable schizophrenic patients maintained with
      risperidone.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prolactin level</measure>
    <time_frame>baseline, 2 weeks, 4 weeks, 8 weeks</time_frame>
    <description>Change from baseline in the levels of prolactin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PANSS (positive and negative syndrome scale) score</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Change from baseline in PANSS score</description>
  </secondary_outcome>
  <other_outcome>
    <measure>extrapyramidal symptoms</measure>
    <time_frame>baseline, 4 weeks, 8 weeks</time_frame>
    <description>assess the extrapyramidal symptoms</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>risperidone plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aripiprazole 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>risperidone treatment plus aripiprazole 5mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aripiprazole 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>risperidone plus aripiprazole 10mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aripiprazole 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>risperidone plus aripiprazole 20mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <arm_group_label>aripiprazole 5mg</arm_group_label>
    <arm_group_label>aripiprazole 10mg</arm_group_label>
    <arm_group_label>aripiprazole 20mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. aged 18-45 years of and fulfilled Diagnostic and Statistical Manual of Mental
             Disorders(DSM-IV )criteria (American Psychiatric Association, 1994) for schizophrenia;

          2. having a stable psychiatric condition, defined as taking the same dosage of
             risperidone for at least 6 weeks;

          3. being treated with risperidone monotherapy; and presence of hyperprolactinemia
             associated with risperidone.

        Exclusion Criteria:

          1. any other major psychiatric disorder;

          2. significant concurrent medical illnesses, organic brain disorder, history of substance
             and alcohol abuse, and mental retardation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jingxu Chen, master</last_name>
    <phone>86-13681394260</phone>
    <email>chenjx1110@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing HuiLongGuan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>102208</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingxu Chen</last_name>
      <phone>86-13681394260</phone>
      <email>chenjx1110@163.com</email>
    </contact>
    <investigator>
      <last_name>Jingxu Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2013</study_first_submitted>
  <study_first_submitted_qc>December 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2013</study_first_posted>
  <last_update_submitted>December 11, 2013</last_update_submitted>
  <last_update_submitted_qc>December 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing HuiLongGuan Hospital</investigator_affiliation>
    <investigator_full_name>Jingxu Chen</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>Risperidone;</keyword>
  <keyword>Aripiprazole;</keyword>
  <keyword>Hyperprolactinemia;</keyword>
  <keyword>dose effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Hyperprolactinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

